pp-270 Solution for injection/infusion
Dossier type
US CTD
Dossier status
Under development
Country of origin
United States
GMP approvals
FDA
Comments
Indication: Diabetes mellitus, Insulin dependent diabetes
Clinical stage: Phase 3
Modality: Peptide
Mechanism & Target: Protein target
Route & form: SC injection / IV infusion
Differentiation: Ultra-fast insulins, i.e. prandial insulins that are even faster than current fast-acting insulins, answer to the need for an optimized insulin-controlled prandial glycaemia. Ultra-fast insulins would allow patients to inject at or during the meal while preserving an ideal glycemic control.
Manufacturer #39682
A late-stage clinical biopharmaceutical company focused on metabolic diseases. Developing a biologic therapeutic targeting metabolic diseases with global development focus. Pipeline positioned for regulatory advancement in key markets.
None